

Giulia Valeria Bianchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8918961/publications.pdf>

Version: 2024-02-01

40
papers

5,969
citations

304743

22
h-index

330143

37
g-index

40
all docs

40
docs citations

40
times ranked

6075
citing authors

#	ARTICLE	IF	CITATIONS
1	The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. <i>Molecular Oncology</i> , 2022, 16, 2355-2366.	4.6	3
2	Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9). <i>Breast Cancer Research and Treatment</i> , 2021, 190, 103-109.	2.5	3
3	Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2021, 32, 994-1004.	1.2	393
4	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020, 15, 30-37.	1.4	0
5	Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Cancers</i> , 2020, 12, 3314.	3.7	5
6	Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. <i>Cancers</i> , 2020, 12, 617.	3.7	4
7	Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. <i>PLoS ONE</i> , 2019, 14, e0220644.	2.5	6
8	Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 53-66.	4.4	137
9	Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study. <i>Breast Journal</i> , 2019, 25, 237-242.	1.0	1
10	Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. <i>Cancers</i> , 2019, 11, 1753.	3.7	16
11	Eribulin in "Field Practice": More from the Italian Experience. <i>Oncology</i> , 2018, 94, 1-2.	1.9	4
12	Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?. <i>Clinical Breast Cancer</i> , 2018, 18, e363-e371.	2.4	14
13	Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 16.	5.0	83
14	Evaluation of Local Oncologic Safety in Nipple-Areola Complex-sparing Mastectomy After Primary Chemotherapy: A Propensity Score-matched Study. <i>Clinical Breast Cancer</i> , 2017, 17, 219-231.	2.4	28
15	Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, E403-E407.	1.4	3
16	5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. <i>Lancet Oncology</i> , The, 2016, 17, 791-800.	10.7	623
17	Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy. <i>Breast</i> , 2016, 29, 90-95.	2.2	31
18	Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge. <i>Future Oncology</i> , 2016, 12, 1413-1428.	2.4	24

#	ARTICLE	IF	CITATIONS
19	Current challenges in HER2-positive breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 211-221.	4.4	33
20	Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. <i>Oncotarget</i> , 2016, 7, 255-265.	1.8	39
21	Did Circulating Tumor Cells Tell us all they Could? The Missed Circulating Tumor Cell Message in Breast Cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 429-433.	1.8	26
22	¹⁸ F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 818-830.	6.4	34
23	Prognosis of women with early breast cancer and PIK3CA mutations. <i>Breast</i> , 2015, 24, 283-284.	2.2	3
24	Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. <i>Annals of Oncology</i> , 2015, 26, 2429-2436.	1.2	106
25	Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations. <i>Future Oncology</i> , 2015, 11, 2251-2254.	2.4	1
26	Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: A randomized clinical trial (INT09/98). <i>Cancer</i> , 2014, 120, 885-893.	4.1	68
27	Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: Results and clinical implications after eight-years follow-up. <i>Breast</i> , 2014, 23, 334-340.	2.2	1
28	Commentaries on Data Published by Riggio et al. and Discussion by Otterburn on Locoregional Risk Following Mastectomy After Lipofilling. <i>Aesthetic Plastic Surgery</i> , 2014, 38, 608-610.	0.9	1
29	Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1157-1163.	1.6	342
30	Lapatinib and letrozole as first-line therapy for metastatic breast cancer: case report of bone metastasis 18 years later. <i>Tumori</i> , 2013, 99, 264e-8e.	1.1	0
31	Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available. <i>Tumori</i> , 2013, 99, 269e-72e.	1.1	4
32	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2012, 13, 25-32.	10.7	1,879
33	Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1594-1600.	1.6	221
34	Pertuzumab - a HER-2 Dimerisation Inhibitor - for the Treatment of Breast and Other Cancers. , 2011, , 73-90.		0
35	Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1131-1137.	1.6	214
36	Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 1138-1144.	1.6	593

#	ARTICLE	IF	CITATIONS
37	Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2630-2637.	1.6	582
38	Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2009, 20, 616-624.	1.4	102
39	The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute Common Toxicity Scale. <i>Journal of the Peripheral Nervous System</i> , 2007, 12, 210-215.	3.1	204
40	Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. <i>European Journal of Cancer</i> , 2005, 41, 1746-1750.	2.8	138